Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Sage Theraputic RG (SAGE)

13 Jul 2018 07:17 PM

04 Jun 2018 02:54 PM

02 Jun 2018 11:18 PM <--

Return to Sage Theraputic RG (SAGE)

Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical company focused on diseases affecting the central nervous system (CNS). Based in Boston, SAGE has a portfolio of drug candidates that modulate the gamma-aminobutyric acid (GABA) system. SAGE-547 is in development for and postpartum depression. Orally dosed SAGE-217 is in development for postpartum depression, major depressive disorder, essential tremor and Parkinson's disease.[copied from BoAML (ML)]

ML currently has a BUY on SAGE with a 12 month $200. price objective. Morgan Stanley does not cover it yet.

sagerx.com